Drs. Martinez and Montesi discuss how treatment for ILD, IPF, and PPF has shifted from “nothing we can do” to a complex, rapidly expanding toolbox that now includes multiple antifibrotic options and emerging combination strategies. They stress that these drugs slow progression but don’t cure disease, so real-world decisions hinge on side effects, quality of life considerations, patient goals, and the often frustrating realities of insurance coverage and cost.
Podden och tillhörande omslagsbild på den här sidan tillhör
PeerDirect. Innehållet i podden är skapat av PeerDirect och inte av,
eller tillsammans med, Poddtoppen.